<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>

    <!-- Bootstrap CDN -->
    <link rel="stylesheet" href="css/bootstrap.min.css">

    <!-- Main CSS -->
    <link rel="stylesheet" href="css/style.css">

</head>

<body>

    <div class="fixedHeight bigLineHight">
        <div class="right_shape">
            <a href="../page31/index.html" class="cross_icon_close">
                <img src="img/cross_icon.svg" alt="">
            </a>
            <img src="img/right_silver_shape.png" style="zoom: .5;" alt="">
        </div>
        <div class="container_xxl container-xxl p7_px py-5 z_index9">
            <div class="py-5">
                <div class="pt-5 mt-5">
                    <p class="GothamBold txt_silver refTitle">REFERENCES:</p>
                    <div class="txt_silver GothamBook fs-11">
                        <p class="mb-0">1. Moreau P, et al. N Eng J Med. 2016;374:1621-34</p>
                        <p class="mb-0">2. Hajek R, et al. Future Oncol. 2021; epub ahead of print.</p>
                        <p class="mb-0">3. Chari A, at al. Exp Rev Hematol. 2020;13(4):421-33.</p>
                    </div>
                </div>
                <br>
                <div class="txt_silver p7_p0 p7_br_none fs-11">
                    <p class="GothamBold refTitle">CLINICAL STUDY TITLE:</p>
                    <p class="GothamBook">MM1: Ixazomib (NINLARO) + Rd was General Well-tolerated with Manageable Side Effects</p>
                    <br>
                    <p class="GothamBold">No. of Patients: <span class="GothamBook">361</span></p>
                    <br>
                    <p class="GothamBook"><span class="GothamBold">Trial Design:</span> Real-World Design</p>
                    <br>
                    <p class="GothamBook"><span class="GothamBold">Clinical Endpoints:</span><br> Rates of discontinuation of the full study regimen due to AEs were 17% with Ixazomib (NINLARO) + Rd and 14% with placebo + Rd <br>
                        Rates of dose reduction of any study drug due to AEs were 56% with Ixazomib (NINLARO) + Rd vs 50% with placebo + Rd.</p>
                </div>
            </div>
        </div>
        <div style="height: 100px;"></div>
        <div class="footer_page1 bg-transparent">
            <div class="footer_inner_nav1 bg-transparent footer_inner_nav1_modified_reff">
                <ul class="mb-1 me-1">
                    <li>
                        <a href="../page31/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a class="text-uppercase">ref</a>
                    </li>
                </ul>
            </div>
        </div>
    </div>

</body>

</html>